Today’s Top Three in Pharma 020309

Avastin + Tarceva = better results in lung cancer – Genentech said the trial was stopped early after an interim analysis found that combining Avastin, known generically as bevacizumab, and Tarceva, or erlotinib, significantly extended the time patients with non-small cell lung cancer lived without their disease advancing.

Amylin‘s leadership under fire from Carl Icahn and others – “While we have not lost faith in the potential of Amylin’s products and pipeline, we have lost confidence in Amylin’s leadership to take this rich product portfolio and execute an operational strategy that is in the best interest of the shareholders…”

Does insulin help protect brains from the development of Alzheimer’s? – Insulin appears to shield the brain from toxic proteins associated with Alzheimer’s disease, U.S. researchers said on Monday, supporting a theory that Alzheimer’s may be a third form of diabetes.

PLUS – the usual rumor mill: blah, blah, blah…Sanofi-Aventis…blah, blah, blah…Bristol Myers-Squibb. You know the drill. And, business advice from the NY Times for navigating through a downturn.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS